Home Tags Cancer: Prostate

Tag: Cancer: Prostate

For men with localized prostate cancer

Ultrasound Ablation Offers Option for Some With Prostate Cancer

Bilateral prostate cancer at diagnosis was sole predictor of Grade Group 2 or greater recurrence
For men with nonmetastatic

Darolutamide Boosts Survival in Nonmetastatic Prostate Cancer

Risk for death significantly lower versus placebo in nonmetastatic, castration-resistant prostate cancer
After adjustment for clinical and nonclinical factors

Factors Clarify Racial Disparity in Prostate Cancer Survival

Education, median household income, and insurance status contribute most to racial disparity in the U.S.
For men with prostate cancer

Delayed Radiotherapy Not Tied to Worse Survival in Prostate Cancer

Initiation of RT up to six months after androgen deprivation therapy not tied to worse overall survival
As a result of the Philadelphia Prostate Cancer Consensus Conference

Guidance Issued for Genetic Testing in Prostate Cancer

Germline testing advised for metastatic disease, family history suggestive of hereditary disease
For men with prostate cancer

Delayed Radiotherapy Not Tied to Worse Survival in Prostate Cancer

Initiation of RT up to six months after androgen deprivation therapy not tied to worse overall survival
Prostate cancer clinical trial participants are overwhelmingly white

Prostate Cancer Trial Participants Overwhelmingly White

Since 1990, proportion of white participants in prostate cancer clinical trials has remained >80 percent
For men with advanced prostate cancer

ASCO: Relugolix Superior to Leuprolide in Advanced Prostate Cancer

And, enzalutamide improves median overall survival in nonmetastatic, castration-resistant prostate cancer
Prostate cancer incidence rates decreased from 2005 to 2016 for local-stage disease among men aged ≥50 years but increased for regional- and distant-stage disease

Local-Stage Prostate Cancer Incidence Rates Continue to Drop

Rates of regional- and distant-stage prostate cancer increasing in the U.S. among men aged ≥50 years
Among prostate cancer patients

Risk for SARS-CoV-2 Lower for Prostate Cancer Patients on ADT

Risk reduced fourfold with androgen-deprivation therapy versus other treatment for prostate cancer